Source: Annual Congress 2002 - Drug resistance
Disease area: Respiratory infections

Abstract

The aim of the study was to evaluate bacteriostatic blood activity (BBA) against M.tuberculosis strains, isolated from patients with pulmonary destructive tuberculosis during intensive polychemotherapy. We used the method of microcultivation M. tuberculosis on glasses. BBA was studed in 65 patients with newly diagnosed pulmonary destructive tuberculosis against strains isolated from these patients. Primary antituberculosis drug resistance had 26,1% of patients (multiresistance- in 3,0%, polyresistance- in 6,1% of cases). All patients recived polychemotherapy regimens consisted of 5-6 basic antituberculosis drugs with using 5 drugs per day. During 24 hours only high BBA levels (bacteriostasis was seen at 32- 512 - fold blood dilutions) were determined at 35,4 % of persons against antituberculosis drug sensitive strains of M.tuberculosis, isolated from these patients, and relatively drug resistant M.tuberculosis strains -at 5,8 % (p < 0,05), low and high BBA levels (bacteriostasis at 4- 512- fold blood dilutions) accordingly in 0 % and 47,2 % (p < 0,05), average and high levels (bacteriostasis at 16- 512- fold blood dilutions) at 64,6 % and 47,0 % of cases. Antituberculosis drug resistance, in particulary multy- and polyresistence, hinder from preservation total BBA on high or high and average level during 24 hours

Rating:

Share or cite this content

Citations should be made in the following way:
Z. E. Vyalykh (Kyiv, Ukraine). Dependending on drug resistance character of bacteriostatic blood activity at time polychemotherapy against of M. tuberculosis strains isolated from patients. Eur Respir J 2002; 20: Suppl. 38, 3833

Member's Comments

No comment yet.

Related content which might interest you: Change of M. tuberculosis drug susceptibility spectrum during chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 11s Year: 2006 Treatment of resistant tuberculosis in patients having isolates resistant to multiple antituberculosis drugs Source: Annual Congress 2010 - Prognosis of tuberculosis Year: 2010 Susceptibility of Mycobacterium tuberculosis strains to fluoquinolones, obtained from chronic patients with multidrug resistant pulmonary tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 315s Year: 2001 The use of the lytic D29 mycobacteriophages for accelerated determination of the drug sensitivity of tuberculosis mycobacteria to first and second-line anti-TB drugs in clinical isolates obtained after initial cultivation Source: Virtual Congress 2020 – Tuberculosis: part 2 Year: 2020 Relationship between rpoB mutations and minimum inhibitory concentrations of rifampicin in multi drug resistant strains of mycobacterium tuberculosis Source: Annual Congress 2011 - Tuberculosis: from bench to bedside Year: 2011 Recommending prolonged bedaquiline use for the treatment of highly resistant strains of tuberculosis Source: Eur Respir J, 50 (5) 1701552; 10.1183/13993003.01552-2017 Year: 2017 Minimal inhibitory concentrations (MIC) of first line drugs in multidrug resistant strains of M. tuberculosis (MDR-TB) Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 The effects of drug resistance phenotype on proliferation of Mycobacterium tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004 The efficacy of treatment of patients with drug resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007 The Glutoxim influence on minimum inhibitory concentration of isoniazid-resistant strains of Mycobacterium tuberculosis Source: International Congress 2019 – Tuberculosis: from basic science to patient care Year: 2019 Antituberculosis activity of rifabutin in vitro and in patients with pulmonary drug resistant tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003 The peculiarities of drug susceptibility of M. tuberculosis isolated from patients with late-stage HIV infection Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 In vitro and vivo study of isoxyl, a mycolic acid inhibitor for intermittent chemotherapy of multi drug resistant (MDR) strains of mycobacterium tuberculosis (M.tb) Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006 Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 339s Year: 2001 Detection of isoniazid or rifampin resistant Mycobacterium tuberculosis in patients with cavity and previously treated for tuberculosis - usefulness of rapid drug susceptibility test with sputum samples by reverse hybridization assay Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005 Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains Source: Eur Respir J 2015; 45: 287-289 Year: 2015 Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains Source: Eur Respir J 2015; 45: 285-287 Year: 2015 The peculiarities of course and treatment of pulmonary tuberculosis with initial drug resistance Source: Eur Respir J 2003; 22: Suppl. 45, 41s Year: 2003 A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis Source: Eur Respir J, 51 (2) 1702166; 10.1183/13993003.02166-2017 Year: 2018 Isoniazid resistance is associated with delayed culture conversion during anti-tuberculosis treatment among patients with pulmonary tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018